Zhejiang Langhua Pharmaceutical, a wholly owned subsidiary of Viva Biotech, (HKG:1873), passed the current good manufacturing practices (cGMP) onsite inspection conducted by the US Food and Drug Administration (FDA), according to a Thursday bourse filing.
The pharmaceutical company recently received the establishment inspection report from the US FDA, confirming the inspection's completion in line with the Code of Federal Regulations Title 21 (21 CFR).
The inspection, done in the second half of 2024, covered quality systems, materials, production, packaging and labeling systems, equipment and facilities, and laboratory control.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.